Neurogene Inc reports results for the quarter ended in December - Earnings Summary

Neurogene

18/03/2024 21:51

* Neurogene Inc  NGNE.OQ  reported a quarterly adjusted loss
of
$1.51​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of
$-4.80.  The mean expectation of three analysts for the quarter
was for a loss of $1.17 per share. Wall Street expected
results to range from $-1.66 to -92 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Neurogene Inc's reported EPS for the quarter was 23
cents​.
    * The company reported quarterly net income of $2.4 million.
    * Neurogene Inc shares had risen by 93.7% this quarter.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Neurogene Inc is
$44.50 
This summary was machine generated from LSEG data March 18 at
09:50 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.17          -1.51          Missed
                                  -1.64          
                                  -0.80          
 Mar. 31 2023      -2.50          -5.12          Missed